Intima Bioscience

Intima Biosciences is a New York City-based company focused on developing gene and cell therapies aimed at curing solid tumor cancers. The company operates a specialized production facility for Molecular and Cell Therapy (MCT) and is currently conducting a clinical trial at the University of Minnesota Masonic Cancer Center. Its platform is designed to evaluate the safety and efficacy of genetically-engineered, neoantigen-specific tumor-infiltrating lymphocytes, which are intended to inhibit the expansion of gastrointestinal cellular cells. Through these innovative approaches, Intima Biosciences seeks to advance treatment options in the field of oncology.